论文部分内容阅读
目的：为了预估抑制PD-1/PD-L1单抗的单药治疗和/或联合治疗的受益人群,本研究对中国非小细胞肺癌患者进行了一系列肿瘤免疫治疗相关(PD-1,PD-L1和CTLA-4)和肿瘤靶向治疗相关(EGFR突变,KRAS突变,ALK,ROS1重组和MET)生物标记物的研究。
中国非小细胞肺癌患者PD-L1的表达及与其它肺癌驱动基因的关系
【摘 要】
：
目的：为了预估抑制PD-1/PD-L1单抗的单药治疗和/或联合治疗的受益人群,本研究对中国非小细胞肺癌患者进行了一系列肿瘤免疫治疗相关(PD-1,PD-L1和CTLA-4)和肿瘤靶向治疗相关(EGFR突变,KRAS突变,ALK,ROS1重组和MET)生物标记物的研究。
【机 构】
：
上海 上海交通大学附属胸科医院呼吸内科 上海 阿斯利康
【出 处】
：
第十八届全国临床肿瘤学大会暨2015年CSCO学术年会
【发表日期】
：
2015年4期
其他文献
目的：讨论鼻咽癌IMRT后，腮腺区域复发的潜在原因。方法：回顾我院2005年1月至2012年12月鼻咽癌IMRT患者1096例，腮腺复发13例，可分析的腮腺复发12例。以腮腺区域复发侧为病例组，以腮腺区域未复发侧为对照组，进行病例对照研究。
Objective: The progression of pulmonary ground glass nodules (GGNs) was slow, 5 years survival rate of lobe/sublobe resection was close to 100%.In clinical, we also found that the progression of some
Moderate dose-fractionated stereotactic body radiotherapy for medically Inoperable stage Ⅰ non-small
Objective: To investigate the clinical outcomes and toxicity of stereotactic body radiotherapy (SBRT) with amoderate dose fraction for medically inoperable stage Ⅰ non-small cell lung cancer (NSCLC).
Circulating Tumor Cells and Evaluation of Targeted Therapy Effect in EGFR Mutation/ALK Translocation
Objective: Targeted therapies have considerably improved the prognosis of patients with non-small cell lung cancer (NSCLC).Although not precision enough, RESIST criteria was still the most often used
Phase Ⅲ trial of afatinib vs erlotinib in patients (pts) with squamous cell carcinoma (SCC) of the l
Objective: Treatment options for pts with advanced SCC of the lung progressing after platinum-based chemotherapy are limited.Over expression of EGFR, other ErbB receptors and the dysregulation of thei
Predictive and prognostic value of de novo MET expression in patients with advanced non-small cell l
Objective: The cellular-mesenchymal-epithelial transition protein (MET) has recently been identified as a novel promising target in non-small-cell lung cancer (NSCLC) treatment.
Abundance of EGFR Mutations affects the efficacy of EGFR-TKI in patients with EGFR-Mutant advanced l
Objective: The discovery of epidermal growth factor receptor(EGFR) mutations in NSCLC opened the era of individualized therapy.A number of clinical studies have shown the efficacy of EGFR-tyrosine kin
Randomized trial of gefitinib with and without pemetrexed as first-line therapy in East-Asian patien
目的： Pemetrexed (P) is the standard of care for non-squamous non-small cell lung cancer (NS NSCLC)， whereas epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)， such as gefitinib
目的：表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)对伴有EGFR敏感突变的晚期非小细胞肺癌(NSCLC)患者疗效显著。因此,EGFR基因检测对选择合适的患者以及实时监测药物疗效至关重要。
目的：非小细胞肺癌的临床分期影响着治疗方法，不同分期其治疗方法存在明显不同，特别是cN0与cN2.PET-CT是临床上假阴性较低的新型诊断方法，但仍然存在假阴性的情况.本文的目的是探讨提示PET-CTN2假阴性的临床因素.